Medpace Holdings, Inc. $MEDP Shares Purchased by Artemis Investment Management LLP

Artemis Investment Management LLP boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 150.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,503 shares of the company’s stock after buying an additional 56,830 shares during the period. Artemis Investment Management LLP owned about 0.34% of Medpace worth $58,987,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Titleist Asset Management LLC increased its position in Medpace by 13.7% in the 3rd quarter. Titleist Asset Management LLC now owns 473 shares of the company’s stock valued at $295,000 after acquiring an additional 57 shares in the last quarter. Ausbil Investment Management Ltd boosted its holdings in Medpace by 5.1% during the third quarter. Ausbil Investment Management Ltd now owns 4,493 shares of the company’s stock worth $2,804,000 after buying an additional 218 shares during the last quarter. Steph & Co. acquired a new position in Medpace during the third quarter valued at approximately $89,000. Congress Asset Management Co. boosted its position in shares of Medpace by 3.4% during the third quarter. Congress Asset Management Co. now owns 60,479 shares of the company’s stock worth $37,750,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Cim Investment Management Inc. grew its holdings in shares of Medpace by 7.3% in the 2nd quarter. Cim Investment Management Inc. now owns 1,137 shares of the company’s stock valued at $602,000 after buying an additional 77 shares during the period. 77.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MEDP has been the subject of several research analyst reports. BMO Capital Markets upped their price target on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a report on Friday, July 24th. Mizuho lifted their price target on shares of Medpace from $665.00 to $700.00 and gave the company an “outperform” rating in a research note on Wednesday. TD Cowen upped their price target on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price objective on Medpace in a research report on Thursday, July 23rd. Finally, Barclays upped their price target on shares of Medpace from $600.00 to $625.00 and gave the company an “equal weight” rating in a research note on Wednesday. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $607.73.

Medpace Stock Performance

Shares of NASDAQ MEDP traded down $9.38 during midday trading on Thursday, reaching $594.87. The company’s stock had a trading volume of 77,989 shares, compared to its average volume of 328,197. The company has a market cap of $16.60 billion, a P/E ratio of 34.87, a P/E/G ratio of 2.69 and a beta of 1.18. The business’s 50 day moving average price is $601.59 and its two-hundred day moving average price is $524.87. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue was up 17.2% on a year-over-year basis. During the same quarter last year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO August Troendle sold 49,018 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the completion of the sale, the chief executive officer owned 433,372 shares of the company’s stock, valued at approximately $272,205,286.92. This represents a 10.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 336,140 shares of company stock valued at $208,008,328 over the last three months. 20.50% of the stock is owned by insiders.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.